我院静脉用药集中调配中心抗肿瘤药物成品输液质量控制
x

请在关注微信后,向客服人员索取文件

篇名: 我院静脉用药集中调配中心抗肿瘤药物成品输液质量控制
TITLE:
摘要: 目的:有效控制静脉用药集中调配中心(PIVAS)抗肿瘤药物成品输液的配制质量,保证临床用药安全。方法:针对成品输液配制的操作流程,我院PIVAS从配制前、配制中、配制后三个方面对抗肿瘤药物进行全面质量控制,并比较实施前后的控制效果。结果:通过对抗肿瘤药物实施特殊分类管理及医嘱审核管理实施了配制前管理;通过对配制环境、溶剂的选择、混合调配的方法、加药顺序和剂量的管理实施了配制中管理;通过对成品输液进行规范的检查及送达时间和送达条件的管理实施了配制后管理。实施5个月后,我院PIVAS与临床科室就相关问题进行沟通的发生次数由30次减少到10次,成品输液质量问题发生率由0.68%下降至0.18%。结论:通过对抗肿瘤药物配制前、配制中、配制后流程操作进行规范化管理,可对抗肿瘤药物成品输液的质量进行有效控制,促进临床用药安全。
ABSTRACT: OBJECTIVE: To effectively control the quality of intravenous infusion product of antitumor drugs in PIVAS, and to guarantee the safety of clinical drug use. METHODS: According to the operation flow of intravenous infusion product, the quality control of anti-tumor drugs was conducted in PIVAS of our hospital from three aspects, i.e. before, during and after admixture. The improvement effect was compared before and after the implementation. RESULTS: Pre-admixture management was carried out through special classification management and medical order check management for antitumor drug; intra-admixture management was carried out through the management of admixture environment, solvent selection, admixture method, order for adding drug, dosage; post-admixture management was carried out through standard examination of infusion product and the management of delivery time and condition. 5 months later, the times of communication between PIVAS and clinical departments was decreased from 30 times to 10 times, and the incidence of infusion product was decreased from 0.68% to 0.18%. CONCLUSIONS: Standard management has been conducted for operation procedure of anti-tumor drugs before, during and after admixture. The quality of intravenous infusion product of antitumor drugs can be effectively controlled to ensure the safety of clinical drug use.
期刊: 2016年第27卷第25期
作者: 庞国勋,赵建群,崔丽贤
AUTHORS: PANG Guoxun,ZHAO Jianqun,CUI Lixian
关键字: 静脉用药集中调配中心;抗肿瘤药物;成品输液;配置;质量控制
KEYWORDS: PIVAS; Antitumor drugs; Intravenous infusion product; Admixture; Quality control
阅读数: 416 次
本月下载数: 6 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!